References
- YabeDSeinYFukushimaMSeinoSβ cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East AsiansCurr Diab Rep20151536
- IwamotoYKashiwagiAYamadaNEfficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled studyDiabetes Obes Metab20101270070820590747
- FoleyJESreenanSEfficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetesHorm Metab Res20094190590919705345
- Pi-SunyerFXSchweizerAMillsDDejagerSEfficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetesDiabetes Res Clin Pract20077613213817223217
- SacksDBMeasurement of hemoglobin A1c: a new twist on the path to harmonyDiabetes Care2012352674268023173136
- KashiwagiADevelopment of the HbA1c international standardization of HbA1c measurement in Japan Diabetes SocietyRinsho Byori2013658559324205699
- AhrénBMathieuCBaderGSchweizerAFoleyJEEfficacy of vildagliptin versus sulfonylureas as add-on to metformin: comparison of results from randomized controlled trials and real-life conditionsDiabetologia2014571304130724682379
- AhrénBFoleyJEThe islet enhancer vildagliptin: mechanisms of improved glucose metabolismInt J Clin Pract Suppl200862suppl 15981418269436
- MøllerJBDalla ManCOvergaardRVEthnic differences in insulin sensitivity, β-Cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysisJ Clin Endocrinol Metab2014994273428025119313